Compare · PAVM vs RMD
PAVM vs RMD
Side-by-side comparison of PAVmed Inc. (PAVM) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PAVM and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $29.87B, about 294.5x PAVM ($101.4M).
- Over the past year, PAVM is down 65.5% and RMD is down 13.3% - RMD leads by 52.3 points.
- PAVM has been more active in the news (14 items in the past 4 weeks vs 6 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 0 for PAVM).
- Company
- PAVmed Inc.
- ResMed Inc.
- Price
- $8.48-2.42%
- $205.03-3.96%
- Market cap
- $101.4M
- $29.87B
- 1M return
- -12.98%
- -8.00%
- 1Y return
- -65.53%
- -13.25%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 14
- 6
- Recent ratings
- 0
- 25
PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest PAVM
- SEC Form DEF 14A filed by PAVmed Inc.
- PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
- SEC Form DEFA14A filed by PAVmed Inc.
- Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
- SEC Form EFFECT filed by PAVmed Inc.
- SEC Form 424B3 filed by PAVmed Inc.
- Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
- Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
- SEC Form S-3 filed by PAVmed Inc.
- SEC Form 4 filed by Lee Victoria Tou-Ho
Latest RMD
- SEC Form 8-K filed by ResMed Inc.
- Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
- Analyst initiated coverage on ResMed
- SEC Form 4 filed by Farrell Michael J.
- SEC Form 4 filed by Sandercock Brett
- SEC Form 4 filed by Farrell Peter C
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026